BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 12866560)

  • 1. A state of extinction: does Food and Drug Administration approval of a prescription drug label extinguish state claims for inadequate warning?
    O'Reilly JT
    Food Drug Law J; 2003; 58(2):287-97. PubMed ID: 12866560
    [No Abstract]   [Full Text] [Related]  

  • 2. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 3. The case for preemption of prescription drug failure-to-warn claims.
    Kim CH
    Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
    [No Abstract]   [Full Text] [Related]  

  • 4. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products.
    Struve CT
    Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970
    [No Abstract]   [Full Text] [Related]  

  • 5. Premarket approval and federal preemption of product liability claims in the wake of Medtronic, Inc. v. Lohr.
    Jarcho DG
    Food Drug Law J; 1996; 51(4):613-8. PubMed ID: 11797730
    [No Abstract]   [Full Text] [Related]  

  • 6. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 7. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 8. [The legal aspects of "off label use" -- or: Doubtful private prescription].
    Internist (Berl); 2008 Mar; 49(3):322-7. PubMed ID: 18327518
    [No Abstract]   [Full Text] [Related]  

  • 9. Federal pre-emption under the Food, Drug & Cosmetic Act from Medtronic, Inc. v. Lohr; Pliva. Inc. v. Mensing.
    Ball FR
    Health Care Law Mon; 2011 Sep; 2011(9):2-8. PubMed ID: 21949984
    [No Abstract]   [Full Text] [Related]  

  • 10. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 11. Drafting warnings for medical products: practical considerations for minimizing litigation.
    Dunne KJ; Patterson KD; Baroumand CR
    Healthspan; 1993 Sep; 10(8):11-20. PubMed ID: 10129147
    [No Abstract]   [Full Text] [Related]  

  • 12. Life after Riegel: a fresh look at medical device preemption one year after Riegel v. Medtronic, Inc.
    Wartman GJ
    Food Drug Law J; 2009; 64(2):291-311. PubMed ID: 19999286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical device preemption after Medtronic, Inc. v. Lohr.
    Neraas MB
    Food Drug Law J; 1996; 51(4):619-29. PubMed ID: 11797731
    [No Abstract]   [Full Text] [Related]  

  • 14. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Misbegotten preemptions.
    Kennedy D
    Science; 2008 May; 320(5876):585. PubMed ID: 18451268
    [No Abstract]   [Full Text] [Related]  

  • 16. Federal preemption of common law tort awards by the Federal Food, Drug, and Cosmetic Act.
    Carrier MK
    Food Drug Law J; 1996; 51(4):509-611. PubMed ID: 11797729
    [No Abstract]   [Full Text] [Related]  

  • 17. Why doctors should worry about preemption.
    Curfman GD; Morrissey S; Drazen JM
    N Engl J Med; 2008 Jul; 359(1):1-3. PubMed ID: 18596269
    [No Abstract]   [Full Text] [Related]  

  • 18. Preemption and malpractice liability.
    Hauser RG
    N Engl J Med; 2009 May; 360(21):2257-8; author reply 2258. PubMed ID: 19458378
    [No Abstract]   [Full Text] [Related]  

  • 19. Recent developments in pharmaceutical products liability law: failure to warn, the learned intermediary defense, and other issues in the new millennium.
    Garbutt BJ; Hofmann ME
    Food Drug Law J; 2003; 58(2):269-86. PubMed ID: 12866558
    [No Abstract]   [Full Text] [Related]  

  • 20. The FDA, preemption, and the Supreme Court.
    Glantz LH; Annas GJ
    N Engl J Med; 2008 May; 358(18):1883-5. PubMed ID: 18450601
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.